ATE412420T1 - Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro - Google Patents

Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro

Info

Publication number
ATE412420T1
ATE412420T1 AT03733748T AT03733748T ATE412420T1 AT E412420 T1 ATE412420 T1 AT E412420T1 AT 03733748 T AT03733748 T AT 03733748T AT 03733748 T AT03733748 T AT 03733748T AT E412420 T1 ATE412420 T1 AT E412420T1
Authority
AT
Austria
Prior art keywords
diagnosing
atherosclerotic plaque
antigen
vitro
chain
Prior art date
Application number
AT03733748T
Other languages
English (en)
Inventor
Evy Lundgren-Akerlund
Original Assignee
Cartela R & D Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201844A external-priority patent/SE0201844D0/xx
Application filed by Cartela R & D Ab filed Critical Cartela R & D Ab
Application granted granted Critical
Publication of ATE412420T1 publication Critical patent/ATE412420T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03733748T 2002-06-17 2003-06-16 Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro ATE412420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38874702P 2002-06-17 2002-06-17
SE0201844A SE0201844D0 (sv) 2002-06-17 2002-06-17 New methods and use

Publications (1)

Publication Number Publication Date
ATE412420T1 true ATE412420T1 (de) 2008-11-15

Family

ID=29738562

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03733748T ATE412420T1 (de) 2002-06-17 2003-06-16 Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro

Country Status (8)

Country Link
US (2) US20050255182A1 (de)
EP (1) EP1589986B1 (de)
JP (1) JP2006510576A (de)
AT (1) ATE412420T1 (de)
AU (1) AU2003239030A1 (de)
CA (1) CA2488423A1 (de)
DE (1) DE60324471D1 (de)
WO (1) WO2003105886A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318706T2 (de) * 2002-06-14 2009-04-30 Cartela R & D Ab Marker für stammzellen und dessen verwendung
BRPI0518328A2 (pt) 2004-11-22 2008-11-11 Ge Healthcare As agente de contraste, composiÇço farmacÊutica, uso de um agente de contraste, mÉtodo para gerar imagens realÇadas de um corpo animal ou humano, e, kit para a preparaÇço de um composiÇço radiofarmacÊutica
MX2008011261A (es) * 2006-03-03 2008-10-28 Activbiotics Pharma Llc Tratamiento de la enfermedad aterosclerotica.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501662A (ja) * 1995-10-18 1999-02-09 シーオーアール セラピュティックス インコーポレイテッド インテグリン−仲介性シグナル変換の調整
AU9016898A (en) * 1997-08-07 1999-03-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Methods and compositions for treatment of restenosis
AU761430B2 (en) * 1998-04-02 2003-06-05 Xintela Ab An integrin heterodimer and a subunit thereof
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody

Also Published As

Publication number Publication date
DE60324471D1 (de) 2008-12-11
AU2003239030A1 (en) 2003-12-31
EP1589986B1 (de) 2008-10-29
WO2003105886A3 (en) 2007-11-01
US20050255182A1 (en) 2005-11-17
CA2488423A1 (en) 2003-12-24
EP1589986A2 (de) 2005-11-02
JP2006510576A (ja) 2006-03-30
US20080159956A1 (en) 2008-07-03
WO2003105886A2 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
DE69522831D1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
DE69817698D1 (de) Verschleisszustandserfassungsvorrichtung für Reifen und Verfahren
ATE458831T1 (de) Verfahren zum nachweis von lungenneoplasmen in fäkalen proben
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ES2188654T3 (es) Nuevos esteres de acridinio hidrofilos funcionalizados.
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
ATE429681T1 (de) System und verfahren zur erkennung von signalartefakten
DE50015973D1 (de) Messgerät mit Seilsonde und Verfahren zum Kürzen der Seilsonde
DE69939269D1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
EP1116029A4 (de) Antikörper für apoptosemarker und anwendungsverfahren
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
DE59813579D1 (de) Verfahren und Diagnosemittel zum Nachweis von Hämostasestörungen
ATE282831T1 (de) Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
EP1643894A4 (de) Verfahren, kits und antikörper zum nachweis von parathyroid
ATE412420T1 (de) Verfahren und verwendungszwecke der integrin alpha 10 kette zur diagnose und nachweis von atherosklerotischer plaquebildung in vitro
ATE422334T1 (de) System und verfahren zur gewebeanalyse
DE69907927D1 (de) Chemilumineszenz-immunoassay zum nachweis eines mit der chagas-erkränkung verbundenen analyts in einer probe
CY1108512T1 (el) Μεθοδος και τυποποιημενη συσκευασια για ανιχνευση της αλκαλικης σφιγγομυελινασης
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
ATE449323T1 (de) Zum nachweisen von erkrankungen der brust geeignete reagenzien und verfahren
ATE392619T1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
EP1212600A4 (de) Diagnostisches reagenz auf der basis von methylen-blau und diagnostischesverfahren zum nachweis von epithel-krebs
HUP0001808A2 (hu) Antitestek, amelyek a laminin nidogén-kötődoménjéhez kötődnek, előállításuk és alkalmazásuk
ATE543914T1 (de) Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties